WO2000008013A2 - 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists - Google Patents

2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists Download PDF

Info

Publication number
WO2000008013A2
WO2000008013A2 PCT/IB1999/001239 IB9901239W WO0008013A2 WO 2000008013 A2 WO2000008013 A2 WO 2000008013A2 IB 9901239 W IB9901239 W IB 9901239W WO 0008013 A2 WO0008013 A2 WO 0008013A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
halo
aromatic
independently selected
Prior art date
Application number
PCT/IB1999/001239
Other languages
English (en)
French (fr)
Other versions
WO2000008013A3 (en
Inventor
Fumitaka Ito
Hirohide Noguchi
Hiroshi Kondo
Original Assignee
Pfizer Pharmaceuticals Inc.
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK99926688T priority Critical patent/DK1102762T3/da
Priority to HU0103567A priority patent/HUP0103567A3/hu
Priority to SK160-2001A priority patent/SK1602001A3/sk
Priority to PL99346211A priority patent/PL346211A1/xx
Priority to EA200100104A priority patent/EA200100104A1/ru
Priority to SI9930151T priority patent/SI1102762T1/xx
Priority to EP99926688A priority patent/EP1102762B1/en
Priority to AT99926688T priority patent/ATE227716T1/de
Priority to EEP200100075A priority patent/EE200100075A/xx
Priority to BR9912778-4A priority patent/BR9912778A/pt
Priority to JP2000563646A priority patent/JP3367945B2/ja
Priority to APAP/P/2001/002063A priority patent/AP2001002063A0/en
Application filed by Pfizer Pharmaceuticals Inc., Pfizer Inc. filed Critical Pfizer Pharmaceuticals Inc.
Priority to NZ509299A priority patent/NZ509299A/en
Priority to CA002339621A priority patent/CA2339621C/en
Priority to AU43859/99A priority patent/AU749166B2/en
Priority to DE69903953T priority patent/DE69903953T2/de
Priority to IL14102999A priority patent/IL141029A0/xx
Priority to UY25659A priority patent/UY25659A1/es
Publication of WO2000008013A2 publication Critical patent/WO2000008013A2/en
Publication of WO2000008013A3 publication Critical patent/WO2000008013A3/en
Priority to IS5812A priority patent/IS5812A/is
Priority to HR970081A priority patent/HRP20010089B1/xx
Priority to NO20010603A priority patent/NO20010603L/no
Priority to BG105301A priority patent/BG105301A/xx
Priority to HK02101444.8A priority patent/HK1040188A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
PCT/IB1999/001239 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists WO2000008013A2 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
NZ509299A NZ509299A (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds as ORL1-receptor agonists
HU0103567A HUP0103567A3 (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists, process for their preparation and pharmaceutical compositions containing the same
CA002339621A CA2339621C (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists
EA200100104A EA200100104A1 (ru) 1998-08-06 1999-07-05 Соединения 2-замещенного-1-пиперидилбензимидазола в качестве агонистов orl1-рецепторов
SI9930151T SI1102762T1 (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists
EP99926688A EP1102762B1 (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists
AT99926688T ATE227716T1 (de) 1998-08-06 1999-07-05 2-substituierte-1-piperidyl- benzimidazolverbindungen als orl1 rezeptor agonisten
EEP200100075A EE200100075A (et) 1998-08-06 1999-07-05 2-asendatud 1-piperidüülbensimidasoolühendid kui ORL-1 retseptori agonistid
BR9912778-4A BR9912778A (pt) 1998-08-06 1999-07-05 Compostos 1-piperidil-benzimidazol 2-substituìdos como agonistas de receptores-orl1
JP2000563646A JP3367945B2 (ja) 1998-08-06 1999-07-05 Ｏｒｌ１レセプターアゴニストとしての２−置換−１−ピペリジルベンゾイミダゾール化合物
APAP/P/2001/002063A AP2001002063A0 (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists.
DK99926688T DK1102762T3 (da) 1998-08-06 1999-07-05 2-substituerede-1-piperidylbenzimidazolforbindelser som ORL1-receptoragonister
SK160-2001A SK1602001A3 (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds, process and intermediates for producing thereof, pharmaceutical compositions and use
PL99346211A PL346211A1 (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists
AU43859/99A AU749166B2 (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds as ORL1-receptor agonists
DE69903953T DE69903953T2 (de) 1998-08-06 1999-07-05 2-substituierte-1-piperidyl-benzimidazolverbindungen als orl1 rezeptor agonisten
IL14102999A IL141029A0 (en) 1998-08-06 1999-07-05 2-substituted-1- piperidyl benzimidazole compounds as orl1-receptor agonists
UY25659A UY25659A1 (es) 1998-08-06 1999-08-13 Procedimiento para preparar compuestos de 1- piperidin benzoimidazol 2- sustituidos como antagonistas de receptores orl1
IS5812A IS5812A (is) 1998-08-06 2001-01-16 2-setin-1-píperidýl bensimídasól efnasambönd sem ORL1-viðtaka gerandefni
HR970081A HRP20010089B1 (en) 1998-08-06 2001-02-02 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists
NO20010603A NO20010603L (no) 1998-08-06 2001-02-05 2-substituert-1-piperidylbenzimidazol forbindelser som ORL 1- reseptor agonister
BG105301A BG105301A (en) 1998-08-06 2001-03-01 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists
HK02101444.8A HK1040188A1 (zh) 1998-08-06 2002-02-26 用作orl1-受體激動劑2-取代的-1-哌啶基苯並咪唑化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IBPCT/IB98/01206 1998-08-06
IBPCT/IB98/01206 1998-08-06

Publications (2)

Publication Number Publication Date
WO2000008013A2 true WO2000008013A2 (en) 2000-02-17
WO2000008013A3 WO2000008013A3 (en) 2000-03-23

Family

ID=11004738

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/001239 WO2000008013A2 (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists

Country Status (44)

Country Link
US (1) US6172067B1 (zh)
EP (1) EP1102762B1 (zh)
JP (1) JP3367945B2 (zh)
CN (1) CN1317968A (zh)
AP (1) AP2001002063A0 (zh)
AR (1) AR018686A1 (zh)
AT (1) ATE227716T1 (zh)
AU (1) AU749166B2 (zh)
BG (1) BG105301A (zh)
BR (1) BR9912778A (zh)
CA (1) CA2339621C (zh)
CZ (1) CZ2001397A3 (zh)
DE (1) DE69903953T2 (zh)
DK (1) DK1102762T3 (zh)
EA (1) EA200100104A1 (zh)
EE (1) EE200100075A (zh)
ES (1) ES2185357T3 (zh)
GE (1) GEP20033000B (zh)
GT (1) GT199900125A (zh)
HK (1) HK1040188A1 (zh)
HN (1) HN1999000105A (zh)
HR (1) HRP20010089B1 (zh)
HU (1) HUP0103567A3 (zh)
ID (1) ID27212A (zh)
IL (1) IL141029A0 (zh)
IS (1) IS5812A (zh)
MA (1) MA26659A1 (zh)
NO (1) NO20010603L (zh)
NZ (1) NZ509299A (zh)
OA (1) OA11590A (zh)
PA (1) PA8477701A1 (zh)
PE (1) PE20000868A1 (zh)
PL (1) PL346211A1 (zh)
PT (1) PT1102762E (zh)
SI (1) SI1102762T1 (zh)
SK (1) SK1602001A3 (zh)
SV (1) SV1999000099A (zh)
TN (1) TNSN99142A1 (zh)
TR (1) TR200100403T2 (zh)
TW (1) TW513424B (zh)
UY (1) UY25659A1 (zh)
WO (1) WO2000008013A2 (zh)
YU (1) YU8201A (zh)
ZA (1) ZA200100900B (zh)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1069124A1 (en) * 1999-07-16 2001-01-17 Pfizer Inc. 2-Benzimidazolylamine compounds as ORL1-receptor agonists
EP1122257A1 (en) * 2000-01-05 2001-08-08 Pfizer Inc. Benzimidazole compounds as ORL1-receptor agonists
WO2003049736A1 (en) * 2001-12-11 2003-06-19 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
EP1342717A1 (en) * 2000-11-15 2003-09-10 Banyu Pharmaceutical Co., Ltd. Benzimidazole derivatives
WO2003082333A1 (fr) 2002-03-29 2003-10-09 Mitsubishi Pharma Corporation Remede contre les troubles du sommeil
WO2005003127A1 (en) * 2003-06-28 2005-01-13 Celltech R & D Limited Bicyclic heteroaromatic derivatives as modulators of cxcr3 function
WO2005028466A1 (en) 2003-09-25 2005-03-31 Solvay Pharmaceuticals B.V. Benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors
US6903085B1 (en) 1999-08-24 2005-06-07 Astrazeneca, Ab Substituted piperidine compounds useful as modulators of chemokine receptor activity
US6949643B2 (en) 2001-04-12 2005-09-27 Astrazeneca Ab Thiazolopytimidines and their use as modulators of chemokine receptor activity
US6958344B2 (en) 2000-02-11 2005-10-25 Astrazeneca Ab Pyrimidine compounds and their use as modulators of chemokine receptor activity
US6958350B2 (en) 2001-02-19 2005-10-25 Astrazeneca Ab Chemical compounds
US6958343B2 (en) 2000-02-11 2005-10-25 Astrazeneca, Ab Thiazolopyrimidines and their use as modulators of chemokine receptor activity
US6960602B2 (en) 2001-03-22 2005-11-01 Astrazeneca Ab Piperidine derivatives as modulators of chemokine receptors
EP1598339A1 (en) * 2001-04-18 2005-11-23 Euro-Celtique S.A. 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
US6989393B2 (en) 2000-03-10 2006-01-24 Astrazeneca Ab Ccr5 modulators benzimidazoles or benzotriazoles
US7071193B2 (en) 2000-10-20 2006-07-04 Astrazeneca Ab 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases
US7192973B2 (en) 2001-11-15 2007-03-20 Astrazeneca Ab Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5)
WO2008003667A2 (en) * 2006-07-03 2008-01-10 Neurosearch A/S Combinations of monoamine reuptake inhibitors and potassium channel activators
WO2009027820A3 (en) * 2007-08-31 2009-04-23 Purdue Pharma Lp Substituted-quinoxaline-type-piperidine compounds and the uses thereof
US7579342B2 (en) 2000-02-23 2009-08-25 Astrazeneca Pteridine compounds for the treatment of psoriasis
US7585867B2 (en) 2002-09-20 2009-09-08 Astrazeneca Ab Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one
US7790883B2 (en) 2003-12-05 2010-09-07 Astrazeneca Ab Process for the preparation of thiazolopyrimidines
US7842817B2 (en) 2005-01-11 2010-11-30 Neurosearch A/S 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
US8143261B2 (en) 1999-10-01 2012-03-27 Astrazeneca Ab Thiazolo (4,5-D) pyrimidine compounds
US8476271B2 (en) 2008-07-21 2013-07-02 Purdue Pharma, L.P. Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators
WO2014102594A3 (en) * 2012-12-27 2014-10-16 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9115127B2 (en) 2010-08-05 2015-08-25 Amgen Inc. Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
US9440957B2 (en) 2012-06-06 2016-09-13 Novartis Ag Compounds and compositions for modulating EGFR Activity
US9656994B2 (en) 2013-03-22 2017-05-23 The Scripps Research Institute Substituted benzimidazoles as nociceptin receptor modulators
US11787788B2 (en) 2014-03-20 2023-10-17 Capella Therapeutics, Inc. Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0401333A3 (en) 2001-04-18 2004-11-29 Euro Celtique Sa Spiropyrazole compounds and pharmaceutical compositions containing them
MXPA03009602A (es) * 2001-04-18 2004-04-02 Euro Celtique Sa Analogos de nociceptina.
DK1975164T3 (da) 2001-04-18 2010-05-25 Euro Celtique Sa Octahydrobenzimidazolon-forbindelser som analgetika
ES2316559T3 (es) 2001-04-18 2009-04-16 Euro-Celtique S.A. Compuestos espiroindeno y espiroindano.
WO2003004034A1 (en) * 2001-07-02 2003-01-16 Omeros Corporation Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
DE10252665A1 (de) * 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
DE10252666A1 (de) 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
WO2005060947A2 (en) * 2003-12-19 2005-07-07 Sri International Agonist and antagonist ligands of the nociceptin receptor
JPWO2006038738A1 (ja) * 2004-10-08 2008-05-15 武田薬品工業株式会社 受容体機能調節剤
CN101595100B (zh) 2007-01-16 2014-06-11 普渡制药公司 作为orl-1配体的杂环取代的哌啶
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
PL2800737T3 (pl) 2012-01-06 2020-11-02 Novus International Inc. Środki powierzchniowo czynne na bazie sulfotlenku
US9011832B2 (en) 2012-02-09 2015-04-21 Novus International, Inc. Heteroatom containing cyclic dimers
MX2015000395A (es) 2012-07-12 2015-04-10 Novus Int Inc Composiciones de matriz y capa para proteccion de bioactivos.
US9085561B2 (en) * 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
CN108291055B (zh) 2015-11-12 2021-07-06 诺华丝国际股份有限公司 作为溶剂的含硫化合物
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318900A (en) * 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
WO1997040035A1 (en) * 1996-04-19 1997-10-30 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5297978A (en) * 1976-06-02 1977-08-17 Yoshitomi Pharmaceut Ind Ltd Preparation of alicyclic derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
ATE233812T1 (de) 1995-08-15 2003-03-15 Euroscreen Sa Peptide mit pronociceptiveigenschaften
US5866346A (en) 1995-09-27 1999-02-02 Indiana Unversity Foundation Methods of using dynorphins as ligands for XOR1 receptor
EP0813065A3 (en) 1996-06-13 1998-07-22 F. Hoffmann-La Roche Ag Modulation of LC132 (opioid-like) receptor function
EP0829481A1 (en) * 1996-09-16 1998-03-18 Pfizer Inc. Morphinan hydroxamic acid compounds
US5718912A (en) * 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
DE69826278T2 (de) 1997-05-30 2005-11-10 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazol-derivate
AU8334298A (en) 1997-07-15 1999-02-10 Novo Nordisk A/S Nociceptin analogues
US5929035A (en) 1998-04-14 1999-07-27 Regents Of The University Of Michigan Methods of treating intestinal disorders
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318900A (en) * 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
WO1997040035A1 (en) * 1996-04-19 1997-10-30 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1069124A1 (en) * 1999-07-16 2001-01-17 Pfizer Inc. 2-Benzimidazolylamine compounds as ORL1-receptor agonists
US6903085B1 (en) 1999-08-24 2005-06-07 Astrazeneca, Ab Substituted piperidine compounds useful as modulators of chemokine receptor activity
US8143261B2 (en) 1999-10-01 2012-03-27 Astrazeneca Ab Thiazolo (4,5-D) pyrimidine compounds
EP1122257A1 (en) * 2000-01-05 2001-08-08 Pfizer Inc. Benzimidazole compounds as ORL1-receptor agonists
US6861425B2 (en) 2000-01-05 2005-03-01 Pfizer, Inc. Benzimidazole compounds as ORL1-receptor agonists
US6958344B2 (en) 2000-02-11 2005-10-25 Astrazeneca Ab Pyrimidine compounds and their use as modulators of chemokine receptor activity
US6958343B2 (en) 2000-02-11 2005-10-25 Astrazeneca, Ab Thiazolopyrimidines and their use as modulators of chemokine receptor activity
US7579342B2 (en) 2000-02-23 2009-08-25 Astrazeneca Pteridine compounds for the treatment of psoriasis
US6989393B2 (en) 2000-03-10 2006-01-24 Astrazeneca Ab Ccr5 modulators benzimidazoles or benzotriazoles
US7071193B2 (en) 2000-10-20 2006-07-04 Astrazeneca Ab 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases
EP1342717A4 (en) * 2000-11-15 2005-02-16 Banyu Pharma Co Ltd benzimidazole derivatives
US6969712B2 (en) 2000-11-15 2005-11-29 Banyu Pharmaceutical Co., Ltd. Benzimidazole derivatives
EP1342717A1 (en) * 2000-11-15 2003-09-10 Banyu Pharmaceutical Co., Ltd. Benzimidazole derivatives
US6958350B2 (en) 2001-02-19 2005-10-25 Astrazeneca Ab Chemical compounds
US6960602B2 (en) 2001-03-22 2005-11-01 Astrazeneca Ab Piperidine derivatives as modulators of chemokine receptors
US6949643B2 (en) 2001-04-12 2005-09-27 Astrazeneca Ab Thiazolopytimidines and their use as modulators of chemokine receptor activity
EP1598339A1 (en) * 2001-04-18 2005-11-23 Euro-Celtique S.A. 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
US7192973B2 (en) 2001-11-15 2007-03-20 Astrazeneca Ab Piperidine derivatives and their use as modulators of chemokine receptor activity (especially CCR5)
WO2003049736A1 (en) * 2001-12-11 2003-06-19 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
WO2003082333A1 (fr) 2002-03-29 2003-10-09 Mitsubishi Pharma Corporation Remede contre les troubles du sommeil
US8003669B2 (en) 2002-03-29 2011-08-23 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
US7566728B2 (en) 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
US7585867B2 (en) 2002-09-20 2009-09-08 Astrazeneca Ab Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one
WO2005003127A1 (en) * 2003-06-28 2005-01-13 Celltech R & D Limited Bicyclic heteroaromatic derivatives as modulators of cxcr3 function
WO2005028466A1 (en) 2003-09-25 2005-03-31 Solvay Pharmaceuticals B.V. Benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors
US7790883B2 (en) 2003-12-05 2010-09-07 Astrazeneca Ab Process for the preparation of thiazolopyrimidines
US7842817B2 (en) 2005-01-11 2010-11-30 Neurosearch A/S 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
WO2008003667A3 (en) * 2006-07-03 2008-03-20 Neurosearch As Combinations of monoamine reuptake inhibitors and potassium channel activators
WO2008003667A2 (en) * 2006-07-03 2008-01-10 Neurosearch A/S Combinations of monoamine reuptake inhibitors and potassium channel activators
KR101527842B1 (ko) * 2007-08-31 2015-06-22 퍼듀 퍼머 엘피 치환-퀴녹살린-형 피페리딘 화합물 및 그의 용도
EP3101018A1 (en) * 2007-08-31 2016-12-07 Purdue Pharma L.P. Substituted-quinoxaline-type-piperidine compounds and the uses thereof
CN101878208A (zh) * 2007-08-31 2010-11-03 普渡制药公司 取代的喹喔啉型哌啶化合物及其用途
EP2433937A1 (en) * 2007-08-31 2012-03-28 Purdue Pharma LP Substituted-quinoxaline-type-piperidine compounds and the uses thereof
EP2433936A1 (en) * 2007-08-31 2012-03-28 Purdue Pharma LP Substituted-quinoxaline-type-piperidine compounds and the uses thereof
EP2433935A1 (en) * 2007-08-31 2012-03-28 Purdue Pharma LP Substituted-quinoxaline-type-piperidine compounds and the uses thereof
EP3564240A1 (en) * 2007-08-31 2019-11-06 Purdue Pharma L.P. Piperidine intermediates
US8846929B2 (en) 2007-08-31 2014-09-30 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
PH12013500913A1 (en) * 2007-08-31 2019-01-14 Shionogi & Co Substituted-quinoxaline-type-piperidine compounds and the uses thereof
WO2009027820A3 (en) * 2007-08-31 2009-04-23 Purdue Pharma Lp Substituted-quinoxaline-type-piperidine compounds and the uses thereof
US9527840B2 (en) 2007-08-31 2016-12-27 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
AU2008291823B2 (en) * 2007-08-31 2012-02-23 Purdue Pharma L.P. Substituted-quinoxaline-type-piperidine compounds and the uses thereof
US9278967B2 (en) 2007-08-31 2016-03-08 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
US9145408B2 (en) 2008-07-21 2015-09-29 Purdue Pharma L.P. Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators
US9890164B2 (en) 2008-07-21 2018-02-13 Purdue Pharma, L.P. Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators
US8476271B2 (en) 2008-07-21 2013-07-02 Purdue Pharma, L.P. Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators
US10519156B2 (en) 2008-07-21 2019-12-31 Purdue Pharma L.P. 9′-Aza[3,9′-bi(bicyclo[3.3.1]nonan)]-3′-one and preparation thereof
US11111246B2 (en) 2008-07-21 2021-09-07 Purdue Pharma L.P. Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds
US9115127B2 (en) 2010-08-05 2015-08-25 Amgen Inc. Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
US9440957B2 (en) 2012-06-06 2016-09-13 Novartis Ag Compounds and compositions for modulating EGFR Activity
WO2014102594A3 (en) * 2012-12-27 2014-10-16 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9656994B2 (en) 2013-03-22 2017-05-23 The Scripps Research Institute Substituted benzimidazoles as nociceptin receptor modulators
US11787788B2 (en) 2014-03-20 2023-10-17 Capella Therapeutics, Inc. Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof

Also Published As

Publication number Publication date
DK1102762T3 (da) 2002-12-16
TNSN99142A1 (fr) 2005-11-10
TR200100403T2 (tr) 2001-07-23
EA200100104A1 (ru) 2001-08-27
HRP20010089A2 (en) 2002-02-28
GEP20033000B (en) 2003-06-25
NO20010603L (no) 2001-04-05
HRP20010089B1 (en) 2003-04-30
HUP0103567A3 (en) 2003-01-28
NZ509299A (en) 2003-05-30
ES2185357T3 (es) 2003-04-16
SK1602001A3 (en) 2002-09-10
CZ2001397A3 (cs) 2002-05-15
BR9912778A (pt) 2001-09-25
ZA200100900B (en) 2002-08-28
NO20010603D0 (no) 2001-02-05
DE69903953D1 (de) 2002-12-19
PT1102762E (pt) 2003-02-28
TW513424B (en) 2002-12-11
ATE227716T1 (de) 2002-11-15
OA11590A (en) 2004-08-18
US6172067B1 (en) 2001-01-09
DE69903953T2 (de) 2003-03-27
PA8477701A1 (es) 2000-09-29
JP2002522431A (ja) 2002-07-23
JP3367945B2 (ja) 2003-01-20
MA26659A1 (fr) 2004-12-20
EP1102762A2 (en) 2001-05-30
WO2000008013A3 (en) 2000-03-23
EP1102762B1 (en) 2002-11-13
ID27212A (id) 2001-03-08
HK1040188A1 (zh) 2002-05-31
SV1999000099A (es) 2000-09-05
AP2001002063A0 (en) 2001-03-31
PE20000868A1 (es) 2000-08-31
CN1317968A (zh) 2001-10-17
IL141029A0 (en) 2002-02-10
UY25659A1 (es) 2000-02-23
IS5812A (is) 2001-01-16
GT199900125A (es) 2001-01-27
SI1102762T1 (en) 2003-04-30
PL346211A1 (en) 2002-01-28
BG105301A (en) 2001-12-29
HN1999000105A (es) 2000-11-11
HUP0103567A2 (hu) 2002-02-28
EE200100075A (et) 2002-06-17
CA2339621A1 (en) 2000-02-17
AU4385999A (en) 2000-02-28
CA2339621C (en) 2005-04-05
AR018686A1 (es) 2001-11-28
YU8201A (sh) 2003-07-07
AU749166B2 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
US6172067B1 (en) 2-substituted-1-piperidyl benzimidazole compounds as ORL1-receptor agonists
US6423725B1 (en) 4-(2-keto-1-benzimidazolinyl)piperidine compounds as ORL1-receptor agonists
RU2396257C2 (ru) Производные 4-аминопиперидина
EP1069124B1 (en) 2-Benzimidazolylamine compounds as ORL1-receptor agonists
EP1122257B1 (en) Benzimidazole compounds as ORL1-receptor agonists
AU2008277916B2 (en) Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
US20030078279A1 (en) Spiropiperidine compounds as ligands for ORL-1receptor
US6465478B1 (en) 1,3,8-Triuazaspiro(4,5)decanone compounds as ORL1-receptor agonists
US20030109549A1 (en) 2-Substituted-1-piperidyl benzimidazole compounds as ORL1-receptor agonists
MXPA01001331A (en) 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists
MXPA00007051A (en) 4-(2-keto-1-benzimidazolinyl)piperidine compounds as orl1-receptor agonists
MXPA01000116A (en) Benzimidazole compounds as orl1-receptor agonists
MX2013009611A (es) Sustancias inhibidoras de transportador de glicina.
NZ614321B2 (en) Glycine transporter-inhibiting substances
WO2000031061A1 (fr) Derives de 2-oxo-imidazole
MXPA99009765A (en) 1,3,8-triazaspiro[4.5]decanone compound as orl1-receptor agonist

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-82/01

Country of ref document: YU

Ref document number: 99810857.X

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 1999 369208

Country of ref document: US

Date of ref document: 19990805

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 509299

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 43859/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 141029

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1999926688

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1602001

Country of ref document: SK

Ref document number: PV2001-397

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 200100900

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/001331

Country of ref document: MX

Ref document number: P20010089A

Country of ref document: HR

ENP Entry into the national phase

Ref document number: 2339621

Country of ref document: CA

Ref document number: 2339621

Country of ref document: CA

Kind code of ref document: A

Ref document number: 20010097

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017001548

Country of ref document: KR

Ref document number: 1200100109

Country of ref document: VN

Ref document number: 200100104

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2001/00403

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 1999 105301

Country of ref document: BG

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1999926688

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017001548

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-397

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 43859/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999926688

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017001548

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2001-397

Country of ref document: CZ